Teacher Retirement System of Texas Has $2.24 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Teacher Retirement System of Texas boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 269.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,759 shares of the medical device company’s stock after acquiring an additional 20,974 shares during the quarter. Teacher Retirement System of Texas’ holdings in DexCom were worth $2,237,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after purchasing an additional 214,136 shares in the last quarter. Jennison Associates LLC raised its stake in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Groupama Asset Managment boosted its holdings in shares of DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after acquiring an additional 91,051 shares during the last quarter. Finally, Congress Asset Management Co. increased its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Down 1.9 %

DexCom stock opened at $72.13 on Thursday. The company has a 50 day moving average of $82.96 and a 200-day moving average of $77.07. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $141.99. The stock has a market capitalization of $28.19 billion, a PE ratio of 50.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several research analyst reports. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Morgan Stanley upped their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Cfra Research raised DexCom to a “hold” rating in a research note on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.82.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,009 shares of company stock worth $8,044,178. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.